Transient receptor potential canonical (TRPC) channels are the most prominent nonselective cation channels involved in various diseases. However, the function, clinical significance, and molecular mechanism of TRPCs in colorectal cancer (CRC) progression remain unclear. In this study, we identified that TRPC1 was the major variant gene of the TRPC family in CRC patients. TRPC1 was upregulated in CRC tissues compared with adjacent normal tissues and high expression of TRPC1 was associated with more aggressive tumor progression and poor overall survival. TRPC1 knockdown inhibited cell proliferation, cell-cycle progression, invasion, and migration in vitro, as well as tumor growth in vivo; whereas TRPC1 overexpression promoted colorectal tumor growth and metastasis in vitro and in vivo. In addition, colorectal tumorigenesis was significantly attenuated in Trpc1−/− mice. Mechanistically, TRPC1 could enhance the interaction between calmodulin (CaM) and the PI3K p85 subunit by directly binding to CaM, which further activated the PI3K/AKT and its downstream signaling molecules implicated in cell cycle progression and epithelial-mesenchymal transition. Silencing of CaM attenuated the oncogenic effects of TRPC1. Taken together, these results provide evidence that TRPC1 plays a pivotal oncogenic role in colorectal tumorigenesis and tumor progression by activating CaM-mediated PI3K/AKT signaling axis. Targeting TRPC1 represents a novel and specific approach for CRC treatment.

Oncogenesis (2021)10:67 ; https://doi.org/10.1038/s41389-021-00356-5

INTRODUCTION
Colorectal cancer is one of the most common malignant tumors in the world [1]. Both the incidence and fatality rate of colorectal cancer are increasing rapidly and maintaining an upward trend in developed countries [1, 2]. The molecular mechanisms in colorectal cancer initiation and progression are complex and heterogeneous, involving chromosomal instability, microsatellite instability, and abnormal gene amplification, deletion or expression [3–5]. Alteration of multiple genes, such as oncogene or tumor suppressor gene, leading to disordered signal transduction, is one of the major mechanisms in colorectal cancer. Despite the high prevalence of gene expression change, their role in the pathogenesis of colorectal cancer remains poorly understood [6]. Thus, identification of novel driver genes may uncover oncogenic pathways underlying the initiation and progression of colorectal cancer and discover potential targets for CRC treatment.

TRPC channels are the first identified members in the TRP family and constitute a group of calcium-permeable nonselective cation channels, which mediates the influx of Ca2+ and other cations into the cytosol of cells [7, 8]. Based on their amino acid sequences and functional similarities, the seven mammalian members of the TRPC subfamily fall into four subgroups: TRPC1, TRPC2, TRPC4/5, and TRPC3/6/7 that contribute to a broad spectrum of cellular functions and physiological roles [7, 9]. TRPCs have been shown to emerge as potential regulators in various physiological and pathological processes, such as myocardial hypertrophy [10], angiogenesis [11], and diabetic nephropathy [12]. In recent years, several TRPC members participated in diverse cell functions involved in tumor progression, such as cell proliferation, apoptosis, and migration [13, 14], and the p38-MAPK, JNK, and Ras/Raf1/ERK signaling are involved in these processes [15, 16]. However, investigations on the function, clinical significance, and molecular targets of the TRPC subfamily in CRC progression still remain limited.

In this study, we systematically uncovered the oncogenic role of TRPC1 on colorectal cancer cell functions and tumorigenicity in both primary CRC mice using Trpc1 knockout (Trpc1−/−) and nude mice xenografted with gain or loss of TRPC1 human CRC cells. To explore the potential mechanisms, we performed STRING analysis and found that calmodulin (CaM) was closely related to it. CaM, a small intracellular calcium-binding protein, expressed in all eukaryotic cells and participated in signaling pathways that regulate many crucial processes such as growth, proliferation, and movement [17, 18]. CaM and Phosphatidylinositol 3-kinases (PI3K) are common components of several fundamental intracellular processes, and PI3K activity is enhanced by CaM association with the p85 subunit of PI3K [19]. Whether TRPCs can activate PI3K...
signaling through CaM is largely unknown. Here, we showed that TRPC1 directly interacts with CaM, which promotes molecular interactions between CaM and the PI3K p85 subunit, leading to activation of PI3K/AKT signaling cascade. Thus, TRPC1 plays a pivotal oncogenic role in CRC via activating CaM-mediated PI3K/AKT signaling axis.

**RESULTS**

**TRPC1 upregulation is correlated with tumor progression and poor prognosis of CRC patients**

To identify the correlation between TRPCs and CRC, gene expression data were analyzed in the GENT2 database. The results showed that TRPC1 mRNA expression was significantly higher in colorectal tumor tissues compared to adjacent normal tissues.

![Fig. 1](image)

**Fig. 1** TRPC1 upregulation in CRC is positively correlated with tumor progression and poor prognosis of CRC patients. A Analyses of TRPCs mRNA expression in adjacent normal tissues ($n = 287$) and colorectal tumor tissues ($n = 1994$) in the GENT2 dataset. B Protein expression of TRPC1 in colorectal tumor tissues ($n = 98$) and adjacent normal tissues ($n = 13$) from the local cohort were assessed by IHC. C TRPC1 expression in 13 paired colorectal cancer and adjacent normal tissues from the local cohort were assessed by IHC. D Analyses of the TRPC1 mRNA expression in different CRC tumor stage ($n = 459$) in the TCGA database. E Analyses of TRPC1 mRNA levels in primary colorectal tumors ($n = 365$) and metastasis tumors ($n = 60$) in the TCGA database. F Kaplan–Meier survival analysis of overall survival according to the TRPC1 mRNA expression in CRC patients with stage I/II or stage III/IV in the TCGA database. G Analyses of the TRPC1 protein expression in primary colorectal tumors ($n = 61$) and metastasis tumors ($n = 37$) in local cohort by IHC. I TRPC1 was frequently upregulated in CRC cell lines as determined by Western blot analysis ($n = 3$). **$P < 0.01$ vs. NCM460 group. **$P < 0.01$. 

**Y. Sun et al.**

Oncogenesis (2021) 10:67
Fig. 2  TRPC1 knockdown inhibits cell proliferation and cell-cycle progression in colorectal cancer cells. A MTT assay exhibited that forced expression of TRPC1 promoted cell growth, whereas cell growth was inhibited by TRPC1 knockdown ($n = 5$). B Knockdown of TRPC1 suppressed colony formation in the HCT116 and SW620 cells. Typical results are shown in the left panel along with the statistical analysis in the right panel ($n = 5$). C Forced expression of TRPC1 promoted colony formation in the HT29 and SW620 cells ($n = 5$). D The effects of TRPC1 knockdown on cell cycles in the HCT116 and SW620 cells ($n = 5$). Typical flow cytometric histograms (left panel) and the cell cycle distribution (right panel) were shown. *$P < 0.05$; **$P < 0.01$ vs. control.
CRC tissues ($n = 1994$) compared with normal colorectal tissues ($n = 287$), while other members of the TRPC family did not show any significant change (Fig. 1A). Consistent with the increased TRPC1 mRNA, TRPC1 protein expression also markedly increased 1.26-fold and 1.41-fold in tumor tissues compared with adjacent normal tissues in both individual CRC samples ($n = 98$) and additional 13 pairs of samples in the local cohort (Fig. 1B, C). In general, these data reveal that TRPC1 is aberrantly upregulated in CRC.

To evaluate the clinicopathologic features and prognostic significance of TRPC1, we further investigated the association between TRPC1 and the CRC stage in the TCGA database. There was a striking increase in the mRNA levels of TRPC1 in the advanced stage (III/IV) compared with the early stage (I/II) (Fig. 1D), suggesting that TRPC1 level increases during tumor...
progression. Consistently, the mRNA expression of TRPC1 in the metastasis tumor tissues was significantly higher than the primary colorectal tumor tissues, which indicated that TRPC1 upregulation was related to CRC deterioration (Fig. 1E). Furthermore, the Kaplan–Meier survival analysis indicated that CRC patients with higher levels of TRPC1 had a worse outcome (P < 0.001, Fig. 1F), especially in early-stage (I/II) patients, but not in advanced-stage (III/IV) patients (Fig. 1G). The disease-free survival of CRC patients with high levels of TRPC1 also decreased compared with those with low expression (P = 0.0397, Supplementary Fig. S1B). By contrast, the levels of TRPC3, TRPC4, TRPC6 mRNA do not correlate with the overall survival of CRC patients (Supplementary Fig. S1C). Since TRPC1 was a major changed subtype of TRPC family, it was the focus of the consequent study.

Further analysis of TRPC1 levels in primary and metastatic tumors of human CRC tissue microarray demonstrated that the TRPC1 protein expression was markedly enhanced in human metastatic CRC tissues (Fig. 1H). The protein levels of TRPC1 in four CRC cell lines (HCT116, HT29, SW620, and CaCo2) and human colonic epithelial cell NCM460 were also detected by Western blot. Similarly, the protein levels of TRPC1 were significantly increased in CRC cell lines and TRPC1 expression was related to the invasive capacity of CRC cells (Fig. 1I).

**TRPC1 knockdown suppresses tumor growth and cell-cycle progression in vitro**

To gain insight into the biological role of TRPC1 in CRC, TRPC1 stably overexpressing SW620 and HT29 cells, and TRPC1-stably knockdown HCT116 and SW620 cells were constructed by lentiviral shRNA vectors. Any successful silence or overexpression was identified by fluorescence imaging and Western blot analysis (Supplementary Fig. S2A, B). MTT assays revealed that depletion of TRPC1 caused evident compromised viability in both the HCT116 (55.4% of control at day 8) and SW620 (54.3% of control at day 8) cells. On the contrary, accessorial expression of TRPC1 significantly promoted cell viability both in the SW620 (149.7% of control at day 8) and HT29 (153.1% of control at day 8) cells (Fig. 2A). These results were further validated in colony formation assays (Fig. 2B, C). To investigate the possible mechanism by which TRPC1 promotes CRC cell proliferation, the cell cycle distribution was examined by flow cytometry. TRPC1 knockdown in the HCT116 and SW620 cells markedly decreased the G1 to S phase cell population, with a corresponding increase in the G2 phase population (Fig. 2D), indicating that TRPC1 knockdown causes cell cycle arrest in the G2 phase. These findings uncover that TRPC1 plays an oncogenic role in promoting cell growth and accelerating cell-cycle progression in CRC cells.

**TRPC1 motivates tumor growth and tumorigenesis in vivo**

To further confirm the growth-enhancing effect of TRPC1 in vivo, SW620 cells stably expressing sh-TRPC1 or sh-control, TRPC1 or vector were subcutaneously injected into both dorsal flanks of nude mice for xenotransplantation. The TRPC1 knockdown group demonstrated a smaller mean tumor volume and weight than the control cells and the inhibited rate was 77.2% (Fig. 3A). Moreover, the expression of Ki67, a marker of cell proliferation, in the SW620 xenografted tumors was examined by immunohistochemistry. TRPC1 depletion significantly suppressed Ki67 expression in these xenografts, confirming that TRPC1 knockdown inhibited the proliferation of CRC cells in vivo (Fig. 3B). Contrarily, TRPC1 overexpression markedly facilitated tumor growth, concomitant with increased cell proliferation (Fig. 3C, D). These data provide evidence that TRPC1 markedly accelerates the growth of xenografted colorectal tumors in vivo.

To further determine the tumorigenesis effect of TRPC1 in vivo, a classical AOM/DSS-induced method was used to induce colorectal carcinogenesis in Trpc1−/− mice and WT mice. The specific experimental process is shown in Supplementary Fig. S3A. Similar to human CRC tissues, TRPC1 protein level was significantly higher in the AOM/DSS-induced colorectal tissues of WT mice than those in the control mice (Supplementary Fig. S3B). Compared with control mice, the tumor number and colonic index were significantly augmented to 9.2-fold and 2.9-fold, respectively, in the AOM/DSS-induced WT mice. Importantly, this augmentation was strikingly blunted to 2.6-fold and 1.2-fold, respectively, in the AOM/DSS-induced Trpc1−/− mice (Fig. 3E, F). Consistently, there was significant reduced cell proliferation in tumor tissues of the AOM/DSS- Trpc1−/− mice compared with the AOM/DSS-WT group as analyzed by Ki67 staining (Fig. 3G, H). Collectively, these findings demonstrate that TRPC1 plays an important oncogenic role in motivating tumor growth and tumorigenesis in vivo.

**TRPC1 induces cell invasion and migration in vitro and tumor metastasis in vivo**

To determine the effect of TRPC1 on cell migration and invasion, transwell assays were performed in CRC cells. The results showed that the suppression of TRPC1 resulted in a significantly diminished invasive and migratory potential in both the SW620 and HCT116 cells compared with control cells (Fig. 4A and Supplementary Fig. S4A). In contrast, a marked increase in cell invasion and migration ability was observed in the cells with elevated TRPC1 expression (Fig. 4B and Supplementary Fig. S4B). To further investigate its role on tumor metastasis in vivo, SW620 cells stably expressing TRPC1 or vector were inoculated into the tail vein of nude mice. Compared with the vector group, the overexpression of TRPC1 resulted in a greater lung metastasis burden (200% tumor incidence of control) (Fig. 4C). Moreover, H&E-stained lung sections revealed that TRPC1-overexpressed tumors showed extensive tumor tuberous tissues (Fig. 4D), which is consistent with the increased cell proliferation in metastases lung tissues (Supplementary Fig. S3C). Collectively, these data suggest that TRPC1 induces cell invasion and migration in vitro and tumor metastasis in vivo.

**TRPC1 modulates the expression of multiple biomarkers involved in cell cycle and EMT**

To better understand the mechanism by which TRPC1 regulates the cell cycle progression and metastasis, we detected the expression of several key signaling molecules involved in these
TRPC1 induces cell invasion and migration in vitro and tumor metastasis in vivo. A TRPC1 knockdown inhibited the invasive and migratory capabilities of SW620 cells. Typical results are shown in the upper panel along with the statistical analysis in the lower panel (n = 5). B Overexpression of TRPC1 facilitated the invasive and migratory capabilities of SW620 cells (n = 5). C Images of lung metastasis in nude mice inoculated with vector or TRPC1 overexpressed SW620 cells (n = 4). D Representative H&E stained lung metastases tissues of nude mice. Images were observed under 100× magnification. **P < 0.01.
biological processes. Inhibition of TRPC1 elevated the protein levels of the epithelial marker E-cadherin/CDH1, but reduced the expression of mesenchymal markers, namely, N-cadherin/CDH2, Snail1, and Slug (Fig. 5A and Supplementary Fig. S5A). Contrarily, cells overexpressing TRPC1 showed a significant increase in the levels of N-cadherin, Snail1, and Slug, and a decrease of E-cadherin (Fig. 5B and Supplementary Fig. S5C). Meanwhile, the expressions of some vital cell-cycle regulators were detected by Western blot analysis. TRPC1 knockdown in the SW620 and HCT116 cells markedly reduced the expressions of CyclinB1 and CDK1, which promoted the G2 phase progression (Fig. 5C and Supplementary Fig. S5B). These data demonstrated that both cell cycle and EMT were TRPC1-regulated biological processes.
TRPC1 boosts CRC progression through PI3K/AKT activation

To explore the molecular mechanisms underlying the oncogenic effect of TRPC1, the STRING protein–protein interaction analysis was used to find that TRPC1 was highly related to PI3K/AKT signaling pathway (Fig. 5D). Accumulating evidence supports a crucial role of PI3K/AKT signaling in regulating cell cycle progression, cell proliferation, and metastasis in a variety of tumors [20, 21]. Hence, the phosphorylated levels of PI3K and AKT were analyzed using Western blotting, consistently showing that TRPC1 knockdown significantly reduced their activation, whereas TRPC1 overexpression promoted their phosphorylation in the SW620 cells (Fig. 5E and Supplementary Fig. SSD). To identify the oncogenic effect of TRPC1 through activating PI3K/AKT signaling, HT29 and SW620 cells with accessory expression of TRPC1 were further treated with PI3K inhibitor LY294002. After LY294002 treatment, the increased protein level of phospho-PI3K-induced by TRPC1 overexpression was significantly diminished (Fig. 5F and Supplementary Fig. S5E). Moreover, LY294002 reduced the promoted cell proliferation, invasion, and migration caused by TRPC1 overexpression to the normal inhibitor-treated levels in the SW620 and HT29 cells (Fig. 5G, H, and Supplementary Fig. S6A, B). And LY294002 could restore the expression level of EMT markers protein affected by TRPC1 overexpression (Supplementary Fig. S6C). In addition, when TRPC1 was highly expressed in SW620 cells, the autophagy marker LC3II/LC31 ratio tended to decrease, but the difference was not statistically significant (Supplementary Fig. S6D). The results showed that the activation of PI3K/AKT signaling pathway by TRPC1 had no significant effect on autophagy. Thus, our results indicate that PI3K was the crucial signaling molecule in TRPC1-regulated proliferation, invasion, and migration in CRC cells.

TRPC1 enhances the interaction between CaM and PI3K in CRC cells

In normal colonic epithelial NCM460 cell, TRPC1 cannot directly interact with PI3K (Supplementary Fig. S6E). So, we further analyzed the CaM protein, which was shown as an important intermediate molecule between the TRPC1 and PI3K/AKT signaling pathway through the STRING analysis (Fig. 5D). Intriguingly, the immunofluorescence analysis demonstrated that TRPC1, CaM, and PI3K were highly colocalized in the cytoplasm of CRC cells (Fig. 6A), which was further verified in human CRC tumor tissues and adjacent tissues (Fig. 6B). Consistently, TRPC1 was highly expressed and distinctly colocalized with CaM and PI3K in the tumor tissues of AOM/DSS-induced WT mice, while the colocalization of CaM and PI3K was markedly reduced in the tumor tissues of Trpc1−/− mice (Fig. 6C).

A co-immunoprecipitation experiment was performed to further confirm the protein interaction of TRPC1, CaM, and PI3K. As predicted, there was obvious interaction of CaM and PI3K p85 subunit in the SW620 control cells. Importantly, this binding was distinctly disrupted by TRPC1 knockdown, whereas it was markedly increased in the TRPC1-transfected SW620 cells (Fig. 6D, E). Moreover, there was explicit binding between TRPC1 and PI3K p85 subunit in the SW620 cells with TRPC1 overexpression (Fig. 6D, E), indicating that TRPC1 promoted the interaction between CaM and PI3K by directly binding to CaM, and depletion of TRPC1 may attenuate such binding and then block the PI3K activation.

The oncogenic effect of TRPC1 in CRC is attenuated by silencing CaM

To test whether TRPC1 regulates PI3K/AKT signaling through direct interaction with CaM, we silenced CaM in the TRPC1-transfected SW620 cells. The successful silencing was identified by a Western blot analysis (Supplementary Fig. S2C). CaM silencing significantly diminished the increased protein levels of the phospho-PI3K and phospho-AKT induced by TRPC1 overexpression, but not the total PI3K and AKT protein levels (Fig. 7A and Supplementary Fig. S7A). To further validate this function, cellular proliferation and migration were measured in the siCaM-treated CRC cells. The relative colony formation rate and migration ability of siCaM-treated TRPC1-overexpressed SW620 cells were markedly decreased to 75.8% and 65.8% of the TRPC1-transfected cells, respectively, demonstrating that CaM knockdown had attenuated the oncogenic effect of TRPC1 in CRC cells (Fig. 7B, C). And CaM silencing did not significantly diminish the reduced protein levels of the phospho-PI3K and phospho-AKT induced by TRPC1 knockdown in SW620 cells (Supplementary Fig. S7B). The relative colony formation rate and migration ability of siCaM-treated TRPC1-knockdown SW620 cells were not markedly inhibited compared with the TRPC1-knockdown cells (Supplementary Fig. S7C, D). Additionally, the important scaffold role of CaM in TRPC1-regulated CRC progression was analyzed in the TCGA dataset. There was a positive association between TRPC1 mRNA and CALM1 mRNA expressions (Fig. 7D). Furthermore, we analyzed the overall survival for CaM expression in patients stratified according to high (n = 81) or low (n = 79) TRPC1 expression. It is worth mentioning that CaM expression had no prognostic value in patients with low TRPC1 expression, whereas high CaM expression was associated with lower overall survival in patients with high levels of TRPC1 (Fig. 7E). Cbioportal database analyzed the overall survival for CaM expression in patients stratified according to TRPC1 expression in both PI3K mutation and non-mutation, which were not significantly different (Supplementary Fig. S7E). Collectively, our data provided evidence that TRPC1 exhibits its oncogenic effect by activating CaM-mediated PI3K/AKT signaling axis.

DISCUSSION

TRPCs, besides controlling cation entry, regulate important cellular functions, including cell proliferation, survival, and migration [13, 22]. Recently, the role TRPCs play in tumors is gradually being discovered [14]. However, there has been little research on the effects of TRPCs regulation on CRC progression and the anti-tumor mechanism of its action remains limited. In this study, we revealed the role and mechanism of TRPCs in CRC progression. Among the
six human TRPC subunits, TRPC1 is significantly upregulated in CRC tissues and high levels of TRPC1 significantly correlate with the aggressive characteristics of CRC as well as poor survival in CRC patients. KRAS, BRAF, and PI3K gene mutations promote the occurrence and development of CRC by activating downstream signaling pathways. We also analyzed TRPC1 expression in function of KRAS, BRAF, and PI3K mutational status with the Cbioportal database (data from TCGA). The results show that TRPC1 expression was decreased in CRC patients with KRAS mutation, but no significant difference was observed in PI3K and
BRAF mutation conditions (Supplementary Fig. S1A). Therefore, we modulated TRPC1 level in different CRC cell lines (HCT116 cell line with KRAS mutation, SW620 cell line with KRAS and PIK3CA mutations, and HT29 cell line with BRAF and PIK3CA mutations) and found that the knockdown of TRPC1 reduced cell proliferation, cell-cycle progression, invasion, and migration in vitro, and inhibited tumor growth of the xenograft mice models. Importantly, depletion of Trpc1 significantly suppressed tumorigenesis in vivo. Overexpression of TRPC1 promoted the proliferation, invasion, and migration of colorectal cancer cells. In addition, both in KRAS, BRAF as well as PIK3 mutant and non-mutant CRC cell lines, the change of TRPC1 expression had significant effects on the proliferation, invasion, and migration. Hence, TRPC1 has the independent pleiotropic promoting effects on the genesis, tumor growth, and metastasis of CRC.

Recently, growing evidence suggests that TRPC1 acts as oncogenes in some kinds of malignant tumors. For instance, silencing TRPC1 is able to inhibit the proliferation of hepatocellular carcinoma cells [23], decrease the invasion, migration, and proliferation of thyroid cancer cells via reducing HIF-1α expression [24]. A study for CRC also showed that transcript levels of TRPC1 are upregulated in the HT29 cell line compared with normal cell NCM460 [25]. In the present study, we demonstrated that TRPC1 expression in human CRC tissues was much higher than that in adjacent tissues and negatively correlated with prognosis of CRC patients. Moreover, high levels of TRPC1 positively correlated with TNM stage and tumor metastases in CRC patients. Thus, the meaning of TRPC1 in CRC pathophysiology is strongly suggested. Noticeably, despite TRPC1 being structurally homologous to other subunits of the TRPC family, their distribution and function in various systems are not the same [26]. That may explain why the mRNA expression of other TRPCs is not significantly different between colorectal tumor tissues and adjacent normal tissues.

To further explore the oncogenic role of TRPC1 in CRC, we performed gain of function and loss of function experiments in CRC cell lines and found that TRPC1 knockdown dramatically blocked cell proliferation, migration, and invasion in vitro as well as tumorigenicity in vivo. It has been defined that unscheduled proliferation is often induced by cell cycle defects as well as dysregulation of cyclins and cyclin-dependent kinases (CDKs) complexes [27]. CyclinB1 and CDK1 are important components of the maturation-promoting factors. CDK1 activity requires the binding of a regulatory subunit called Cyclin B1 and the activation of the Cyclin B1/CDK1 complex is responsible for the transition from the G2 to M phase [28]. In this study, TRPC1 knockdown markedly reduced the expressions of CDK1 and CyclinB1, and further caused the arrest of the G2/M transition, which might decline cell proliferation. The development of tumors can be conceptually simplified into two major phases: the first is the genesis, and the second is the growth. Our study firstly discovered that Trpc1 knockout significantly reduced the tumor incidence rate in CRC mice model, suggesting that TRPC1 plays an incitant role in the genesis of CRC. Furthermore, tumor metastases are the cause of 90% of cancer-related deaths [29]. Our findings provided evidence that TRPC1 promoted cell migration and invasion in CRC cells and lung metastasis in mice. TRPC1 exerted its pro-metastatic effect by promoting EMT, as indicated by the loss of the epithelial marker, E-cadherin, and increased the expression of the mesenchymal markers, N-cadherin, Snail1, and Slug, thereby favoring a mesenchymal phenotype that enables increased cell migration and invasion [30, 31]. Collectively, TRPC1 functions as a versatile oncogene in CRC by promoting tumor genesis, growth, and metastasis.

Recent studies have suggested that changes in the intracellular Ca2+ homeostasis may contribute to critical cancer hallmarks, such as enhanced cell proliferation, migration, invasion, and survival [32]. TRPC1 protein is referred to mediate store-operated Ca2+ entry (SOCE), a major mechanism controlling basal Ca2+ levels and intracellular Ca2+ store refilling, which is dynamically enhanced while Ca2+ stores are partially empty in CRC cells [33]. In a previous study, Sajida Ibrahim et al. found that colon cancer cells display an abnormal expression of SOCE molecular players including ORAI1, ORAI3, STIM1, and TRPC1 [34]. Although SOCE is largely upregulated in the HT29, SW480-ADH, and SW480-R CRC cell lines, TRPC1 silencing did not affect SOCE level in the HT29 cell [25]. In our study, calcium imaging assay showed that TRPC1 knockdown could only inhibit the calcium influx in SW620 cells, but had no significant effect on the calcium influx in HCT116 and HT29 cells (Supplementary Fig. S8A and C). But, our experiment showed that TRPC1 knockdown significantly affected the proliferation, invasion, and migration of SW620 and HCT116 cells. Additionally, immunofluorescence assay showed that, besides cytomembrane, TRPC1 also located in the cytoplasm of colorectal cancer cell lines HT29, SW620, and HCT116, which highlighted the possible role of TRPC1 as the cytoplasmic protein in CRC cells (Supplementary Fig. S8D). These results indicate that TRPC1 does not play a major role in the SOCE of CRC cells, and that TRPC1 may perform other functions in CRC progression in addition to acting as a channel protein.

To extensively study the mechanisms responsible for TRPC1-mediated CRC progression, we performed STRING analysis and found that TRPC1 is highly correlated with the PI3K/AKT signaling cascade. It is well-known that the PI3K/AKT pathway plays a crucial role in cell growth and metabolism ultimately in cancer cell survival, proliferation, invasion, and migration [35]. In our study, calcium imaging assay showed that TRPC1 knockdown could only inhibit the calcium influx in SW620 cells, but had no significant effect on the calcium influx in HCT116 and HT29 cells. In the present study, we demonstrated that TRPC1 expression in human CRC tissues was much higher than that in adjacent tissues and negatively correlated with prognosis of CRC patients. Moreover, high levels of TRPC1 positively correlated with TNM stage and tumor metastases in CRC patients. Thus, the meaning of TRPC1 in CRC pathophysiology is strongly suggested. Noticeably, despite TRPC1 being structurally homologous to other subunits of the TRPC family, their distribution and function in various systems are not the same [26]. That may explain why the mRNA expression of other TRPCs is not significantly different between colorectal tumor tissues and adjacent normal tissues.

To further explore the oncogenic role of TRPC1 in CRC, we performed gain of function and loss of function experiments in CRC cell lines and found that TRPC1 knockdown dramatically blocked cell proliferation, migration, and invasion in vitro as well as tumorigenicity in vivo. It has been defined that unscheduled proliferation is often induced by cell cycle defects as well as dysregulation of cyclins and cyclin-dependent kinases (CDKs) complexes [27]. CyclinB1 and CDK1 are important components of the maturation-promoting factors. CDK1 activity requires the binding of a regulatory subunit called Cyclin B1 and the activation of the Cyclin B1/CDK1 complex is responsible for the transition from the G2 to M phase [28]. In this study, TRPC1 knockdown markedly reduced the expressions of CDK1 and CyclinB1, and further caused the arrest of the G2/M transition, which might decline cell proliferation. The development of tumors can be conceptually simplified into two major phases: the first is the genesis, and the second is the growth. Our study firstly discovered that Trpc1 knockout significantly reduced the tumor incidence rate in CRC mice model, suggesting that TRPC1 plays an incitant role in the genesis of CRC. Furthermore, tumor metastases are the cause of 90% of cancer-related deaths [29]. Our findings provided evidence that TRPC1 promoted cell migration and invasion in CRC cells and lung metastasis in mice. TRPC1 exerted its pro-metastatic effect by promoting EMT, as indicated by the loss of the epithelial marker, E-cadherin, and increased the expression of the mesenchymal markers, N-cadherin, Snail1, and Slug, thereby favoring a mesenchymal phenotype that enables increased cell migration and invasion [30, 31]. Collectively, TRPC1 functions as a versatile oncogene in CRC by promoting tumor genesis, growth, and metastasis.
in a variety of pathological and physiological processes by regulating CaM \[40\]. In our study, by using siRNA of CaM, the increased protein levels of p-PI3K and p-AKT induced by TRPC1 overexpression was significantly decreased. Moreover, siCaM could reduce the promoted cell proliferation and migration caused by TRPC1 overexpression close to the normal levels in the SW620 cells. A molecular structure docking assay indicated that activated CaM can specifically bind to the sh2 domain of PI3K regulatory subunit p85, further removing the inhibition of p85 subunit on the catalytic subunit p110, which in turn
activates PI3K signaling [41]. Moreover, the combination of CaM and p85 subunit of PI3K were discovered by a co-IP experiment in bovine aortic endothelial cells [42]. The present study is the first of its kind to reveal that TRPC1, CaM, and PI3K were co-located in CRC cells and tumor tissues using immunofluorescence. Further co-IP assay confirmed that TRPC1 overexpression in CRC cells enhanced the interaction between CaM and PI3K p85 subunit. Noticeably, the interaction between TRPC1 and PI3K p85 subunit were not shown in CRC cells, but appeared in the TRPC1-transfected CRC cells, indicating that CaM is a connexin between TRPC1 and PI3K. Maxime Güeugniou et al. reported that the TRPC1 knockdown inhibited SOCE levels, which reduces p-AKT protein levels and effects the CRC cell migration. While AKT is not a Ca\(^{2+}\) binding protein, the specific data and evidence supporting how does the CaM mediated by this channel complex activates AKT pathway has not been provided and explained [43]. Our findings suggest that TRPC1 can promote the proliferation, invasion, and migration of CRC cells by Ca\(^{2+}\) independent pathway, which directly binds to CaM to promote the binding between CaM and PI3K, and then activate the PI3K/AKT signaling pathway.

CaM, composed of N- and C-terminal domains connected with a flexible linker, has two EF-hand motifs in each domain [18]. It has been reported that a direct interaction between TRPC1 and CaM exists, and the binding domain between CaM and TRPC1 was the EF-hand domain [44, 45], which is different from the binding domain (residues 118–140) between CaM and PI3K [42]. Our study also indicated the three molecular complex between TRPC1, CaM, and PI3K in CRC cells. Based on the different binding sites of the interacting proteins, human TRPC1 (homologous modeling according to TRPC4 protein). CaM, and PI3K proteins were analyzed using the AutoDock 4.2 software to demonstrate the probable binding mechanism by which TRPC1 regulates PI3K (Supplementary Fig. S9). Although the structures of the TRPC family are relatively conservative, the current docking analysis of the interaction site based on homologous modeling TRPC4 protein is limited, since the crystal structure of TRPC1 protein has not been resolved. A direct molecular function of TRPC1 in enhancing the interaction between CaM and PI3K still needs further investigation.

In summary, our findings provided evidence that TRPC1 upregulation is a common event in colorectal cancer and an altered expression of TRPC1 is important for the genesis, tumor growth, and metastasis of CRC. Moreover, our data demonstrate that TRPC1 enhances the interaction between CaM and the PI3K p85 subunit by directly binding to CaM, which further activated the PI3K/AKT and its downstream signaling molecules implicated in cell cycle progression and epithelial-mesenchymal transition (Fig. 7F). Thus, targeting TRPC1 might be a novel strategy for hindering uncontrolled growth and metastasis in PI3K/AKT-addicted colorectal cancer.

**Materials and Methods**

Additional information on reagents and experimental procedures are described in the Supplementary Materials and Methods.

**Statistical Analysis**

Experiments were performed in at least three or five independent replicates. Data are represented as mean ± S.E.M. To analyze all data for statistical significance, SPSS 22.0 (IBM Corp., USA) and GraphPad Prism 8.0 (GraphPad Software, Inc., CA) software were used. The independent or paired two-tailed Student t-test was used to compare the difference between the two groups, and one-way ANOVA was used for multi-group comparisons. Survival curves were evaluated by Kaplan–Meier method and log rank test. The Pearson correlation coefficient was used to evaluate the correlation between the TRPC1 and CALM1 expressions in the clinical samples. The difference in cell viability and tumor growth rate was determined by repeated-measures ANOVA. The value of P < 0.05 was considered statistically significant.

**Data Availability**

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

**References**

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–49

2. Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG, et al. Colorectal cancer. Nat Rev Dis Prim. 2015;5:15065.

3. Yurgelun MB, Kulke MH, Fuchs CS, Allen BA, Uno H, Hornick JL, et al. Cancer susceptibility gene mutations in individuals with colorectal cancer. J Clin Oncol 2017;35:1086–95

4. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol 2011;6:479–507.

5. Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330–7.

6. Dekker E, Tanis PJ, Vleugels J, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394:1467–80.

7. Wang H, Cheng X, Tian J, Xiao Y, Tian T, Xu F, et al. TRPC channels: structure, function, regulation and recent advances in small molecular probes. Pharmacol Ther 2020;209:107497.

8. Curcic S, Schobert R, Schindl R, Groschner K. TRPC-mediated Ca\(^{2+}\) signaling and control of cellular functions. Semin Cell Dev Biol 2019;94:28–38.

9. Chen X, Sooch G, Demaree IS, White FA, Obukhov AG. Transient Receptor Potential Canonical (TRPC) channels: then and now. Cells. 2020;9:1983.

10. Falcón D, Galeano-Otero I, Martín-Bórmé M, Fernández-Velasco M, Gallardo-Castillo I, Rosado JA, et al. TRPC channels: dysregulation and Ca\(^{2+}\) mishandling in ischemic heart disease. Cells. 2020:173.

11. Rodríguez-Moyano M, Diaz I, Dionisio N, Zhang X, Calderón-Escobar E, et al. Urotensin-II promotes vascular smooth muscle cell proliferation through store-operated calcium entry and EGFR transactivation. Cardiovasc Res. 2013;100:297–306.

12. Stauruschken A, Spires D, Palygin O. Role of TRPC6 in progression of diabetic bladder cell growth by enhancing reverse mode of the Na\(^{+}\)/H\(^{+}\) exchanger. Br J Pharm. 2014;171:3432–43.

13. Zhan C, Shi Y. TRPC channels and cell proliferation. Adv Exp Med Biol. 2017;976:149–55.

14. Santoni G, Farfariello V. TRPC channels and cancer: new targets for diagnosis and chemotheraphy. Endocr Metab Immune Disord Drug Targets. 2011;11:54–67.

15. Song M, Chen D, Yu SP. The TRPC channel blocker SKF 96365 inhibits glioblastoma cell growth by enhancing reverse mode of the Na\(^{+}\)/Ca\(^{2+}\) exchanger and increasing intracellular Ca\(^{2+}\). Br J Pharm. 2014;171:3432–47.

16. Ge P, Wei L, Zhang M, Hu B, Wang K, Li Y, et al. TRPC1/3/6 inhibition attenuates the TGF-beta-induced epithelial-mesenchymal transition in gastric cancer via the Ras/Raf1/ERK signaling pathway. Cell Biol Int. 2018;42:975–84.
Chaudhuri P, Rosenbaum MA, Sinharoy P, Damron DS, Birnbaumer L, Graham LM. 
Lin W, Xie J, Xu N, Huang L, Xu A, Li H, et al. Glaucocalyxin A induces G2/M cell 
Zhang M, Jang H, Gaponenko V, Nussinov R. Phosphorylated calmodulin promotes 
Wei R, Xiao Y, Song Y, Yuan H, Luo J, Xu W. FAT4 regulates the EMT and 
Beech DJ. TRPC1: store-operated channel and more. P 
Villalobos C, Hernandez-Morales M, Gutierrez LG, Nunez L. TRPC1 and ORAI1 
Selli C, Erac Y, Kosova B, Erdal ES, Tosun M. Silencing of TRPC1 regulates store-
Wang D, Yu H, Xu B, Xu H, Zhang Z, Ren X, et al. TRPC1 deletion causes striatal 
Sobradillo D, Hernandez-Morales M, Ubierna D, Moyer MP, Núñez L, Villalobos C. A reciprocal shift in transient receptor potential channel 1 (TRPC1) and stromal 
Asghar MY, Magnusson M, Kemppainen K, Sukumaran P, Lidf C, Pulli I, et al. Transient Receptor Potential Canonical 1 (TRPC1) channels as regulators of sphingolipid and VEGF receptor expression: IMPLICATIONS FOR THYROID CANCER CELL MIGRATION AND PROLIFERATION. J Biol Chem 2015;290:16116–31. 
Bonelli P, Tuccillo FM, Borelli A, Schiattarella A, Buonaguro FM. CDK/CCN and CDK1 alterations for cancer prognosis and therapeutic predictivity. Biomed Res Int. 2014;2014:361020. 
Malumbers M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9:153–66. 
Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer. 2006;6:449–58. 
Puisieux A, Brabletz T, Carmel J. Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol 2014;16:488–94. 
Nieto MA, Huang RT, Jackson RA, Thiery JP. Emr. 2016. Cell. 2016;166:21–45. 
Villalobos C, Sobradillo D, Hernandez-Morales M, Nunez L. Calcium remodeling in colorectal cancer. Biochim Biophys Acta, Mol Cell Res 2017;1864:843–9. 
Villalobos C, Hernandez-Morales M, Gutierrez LG, Nunez L. TRPC1 and ORAI1 channels in colon cancer. Cell Calcium. 2019;81:59–66. 
Ibrahim S, Dakh H, Vandler C, Chautard R, Painaud G, Mazurier F, et al. Expression profiling of calcium channels and calcium-activated potassium channels in colorectal cancer. Cancers. 2019;11:561. 
Fresno Varia JA, Casado E, de Castro J, Cejasa P, Belda-Iniesta C, González-Barón M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004;30:193–204. 
Liu JS, Huo CY, Cao HH, Fan CL, Hu JY, Deng LJ, et al. Alopeirine induces apoptosis and G2/M cell cycle arrest in hepatocellular carcinoma cells through the PI3K/Akt signalling pathway. Phytomedicine. 2019;61:152843. 
Lin W, Xie J, Xu N, Huang L, Xu A, Li H, et al. Glaucohocalyxin A induces G2/M cell cycle arrest and apoptosis through the PI3K/Akt pathway in human bladder cancer cells. Int J Biol Sci. 2018;14:418–26. 
Wei R, Xiao Y, Song Y, Yuan H, Luo J, Xu W. FAT4 regulates the EMT and autophagy in colorectal cancer cells in part via the PI3K-AKT signaling axis. J Exp Clin Cancer Res 2019;38:112. 
Gulhati P, Bowen KA, Liu J, Stevens PD, Ryachao PG, Chen M, et al. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res. 2011;71:3246–56. 
Beech DJ. TRPC1: store-operated channel and more. Pflug Arch. 2005;451:53–60. 
Zhang M, Jang H, Gaponenko V, Nussinov R. Phosphorylated calmodulin promotes PI3K activation by binding to the SH2 domains. Biophys J. 2017;113:1956–67. 
Chaudhuri P, Rosenbaum MA, Sinharoy P, Damron DS, Birnbaumer L, Graham LM. Membrane translocation of TRPC6 channels and endothelial migration are regulated by calmodulin and PI3 kinase activation. Cancer Cell. 2016;113:2110–5. 
43. Guéguinou M, Harnois T, Crottes D, Uguen A, Deliot N, Gambade A, et al. SK3/ TRP3C1/Oral1 complex regulates SOCE-dependent colon cancer cell migration: a novel opportunity to modulate anti-EGFR mAb action by the alkyl-lipid Ohmline. Oncotarget. 2016;7:36168–84. 
44. Zhang Z, Tang J, Tikunova S, Johnson JD, Chen Z, Qin N, et al. Activation of Trp3 by inositol 1,4,5-trisphosphate receptors through displacement of inhibitory calmodulin from a common binding domain. Proc Natl Acad Sci USA. 2001;98:3168–73. 
45. Singh BB, Liu X, Tang J, Zhu MX, Ambudkar IS. Calmodulin regulates Ca(2+)-dependent feedback inhibition of store-operated Ca(2+) influx by interaction with a site in the C terminus of Trpc1. Mol Cell. 2002;9:739–50. 

ACKNOWLEDGEMENTS
This work was supported by the National Natural Science Foundation of China (81970245 and 81770432), the Science and Technology Project of Shaanxi Province in China (2019PT-23 and 2019DLSF04–03–01), and the Special Foundation for Talents of Northwest A&F University (2452017335). We thank the department of pathological laboratory, Xijing hospital, Fourth Military Medical University, Xi’an, Shaanxi 710032, China for providing the CRC tissue samples and related anonymous clinical data.

AUTHOR CONTRIBUTIONS
YS, CY, and WT performed experiments, analyzed data, and drafted the manuscript. XQL and WC designed, supervised the experiments, and revised the manuscript. YYG and WY assisted in the establishment of mouse models. YDF and SJW collected the CRC samples and clinical information. GYM and HNZ contributed to the molecular docking experiment. The authors read and approved the final manuscript.

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41389-021-00356-5.

Correspondence and requests for materials should be addressed to Wei Cao or Xiao-Qiang Li.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021

Oncogenesis (2021)10:67

SPRINGER NATURE